Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is …
Biotechnology
CA, Burnaby [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -41.70 | -55.12 | -38.90 | |
| Graham Fair Price | -0.11 | 12.61 | 12.62 | |
| PEG | -34.83 | 5.46 | -8.37 | |
| Price/Book | 4.00 | 3.68 | 3.54 | |
| Price/Cash Flow | -100.00 | -75.40 | 0.00 | |
| Prices/Earnings | -46.63 | -17.05 | -11.63 | |
| Price/Sales | 0.00 | 0.00 | 0.00 | |
| Price/FCF | -100.00 | -75.40 | 0.00 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | 27.78 | -0.05 | -0.07 | |
| ROE | -0.08 | -0.05 | 29.07 | |
| ROIC | -0.08 | -0.07 | 21.32 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.04 | -0.04 | -0.29 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | < 0.005 | -0.10 | -9130.09 | |
| EPS QOQ | -0.01 | 0.03 | 125.00 | |
| FCF QOQ | 1.00 | -0.29 | -71.29 | |
| Revenue QOQ | 0.00 | -1.00 | -100.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.02 | 0.01 | -31.68 | |
| Quick Ratio | 21.32 | 31.52 | 47.85 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 9.65 | 11.44 | 18.61 | |
| Cash | 7.98 | 9.02 | 12.99 | |
| Capex | 0.00 | < 0.005 | -100.00 | |
| Free Cash Flow | 0.00 | -0.56 | -100.00 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad